A New SV2A Ligand for Epilepsy

Research output: Contribution to journalShort survey

6 Citations (Scopus)

Abstract

Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.

Original languageEnglish (US)
Pages (from-to)587
Number of pages1
JournalCell
Volume167
Issue number3
DOIs
StatePublished - Oct 20 2016

Fingerprint

etiracetam
Epilepsy
Nootropic Agents
Ligands
Pharmaceutical Chemistry
Synaptic Vesicles
Animals
Animal Models
Binding Sites

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A New SV2A Ligand for Epilepsy. / Rogawski, Michael A.

In: Cell, Vol. 167, No. 3, 20.10.2016, p. 587.

Research output: Contribution to journalShort survey

Rogawski, Michael A. / A New SV2A Ligand for Epilepsy. In: Cell. 2016 ; Vol. 167, No. 3. pp. 587.
@article{d247e1ad6a85466a948dfcc1fd8dfe8f,
title = "A New SV2A Ligand for Epilepsy",
abstract = "Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.",
author = "Rogawski, {Michael A}",
year = "2016",
month = "10",
day = "20",
doi = "10.1016/j.cell.2016.09.057",
language = "English (US)",
volume = "167",
pages = "587",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - A New SV2A Ligand for Epilepsy

AU - Rogawski, Michael A

PY - 2016/10/20

Y1 - 2016/10/20

N2 - Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.

AB - Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.

UR - http://www.scopus.com/inward/record.url?scp=84994059859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994059859&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2016.09.057

DO - 10.1016/j.cell.2016.09.057

M3 - Short survey

C2 - 27768878

AN - SCOPUS:84994059859

VL - 167

SP - 587

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -